Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bergs Timber in connection with transfer of Berg’s Swedish sawmill business
Mandate

Vinge advises Bergs Timber in connection with transfer of Berg’s Swedish sawmill business

June 18, 2020 Capital Markets and Public M&A

Vinge has advised Bergs Timber AB (publ) in connection with the transfer of the sawmills in Orrefors, Vimmerby, Mörlunda and the assets at the already discontinued operations at Gransjö.

The consideration for the operations, including the working capital involved, is estimated to amount to approximately SEK 400 million, of which SEK 303 million pertains to fixed assets. Bergs Timber has sales of approximately SEK 3.2 billion and is listed on Nasdaq Stockholm.

Vinge’s team has primarily consisted of Jesper Schönbeck, Ulrich Ziche, Joel Wahlberg, Joel Magnusson, Mikaela Falkner, Falkner, Louise Brorsson Salomon, Trine Osen Bergqvist, Kristoffer Larson and Jessica Öijer.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024